2 Billion Doses of COMIRNATY Vaccines Invoiced in 2022

BioNTech SE today reported financial results as of December 31, 2022, and provided an update on its corporate progress.

In December 2022, BioNTech and Pfizer announced that approximately 2 billion doses of COMIRNATY®  were invoiced globally in 2022 between the two companies.

This includes approximately 550 million doses of the Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine as of mid-December 2022.

And as part of BioNTech's and Pfizer's 2-billion-doses-pledge to support equitable access to medicines, the companies have delivered approximately 1.7 billion doses of COMIRNATY to low- and middle-income countries in line with demand.

The deliveries include the Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine and the original COVID-19 vaccine. 

"Our COVID-19 vaccine revenues, driven by the delivery of our Omicron-adapted bivalent vaccines, have ensured another strong financial performance in 2022," said Jens Holstein, CFO of BioNTech, in a press release on March 27, 2023.

"We believe that the Company's financial success in 2022 will provide a springboard to accelerate and build upon our diversified clinical pipeline and fuel our research and development in the coming years. 

The complete press release is posted at this link.